Navigation Links
Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination
Date:3/6/2009

Company Also Receives Going Concern Audit Opinion

ISELIN, N.J., March 6 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS) announced today that it has received a Nasdaq Staff Determination that the company is not in compliance with the minimum $2,500,000 stockholders' equity requirement for continued listing. Unless the company appeals the determination, its securities will be removed from listing and registration on The Nasdaq Stock Market. Pharmos does not intend to appeal the determination. The company anticipates that its shares will be listed for quotation on the Over-the Counter Bulletin Board (OTCBB) or another market and has begun the OTCBB listing process. The company will notify investors of its new stock symbol as soon as it becomes available.

On November 11, 2008, Nasdaq notified Pharmos that it did not comply with the minimum $2,500,000 stockholders' equity requirement for continued listing set forth in Nasdaq Marketplace Rule 4310(c)(3). Based on Nasdaq's review of materials submitted by Pharmos on November 24, 2008, Nasdaq granted the company's request for an exception until February 24, 2009 to comply with the requirement. Upon further review, Nasdaq determined that Pharmos did not meet the terms of the exception in that its stockholders' equity balance was not compliant by February 24, 2009. As a result, trading of Pharmos common stock will be suspended at the opening of business on March 13, 2009, and a Form 25-NSE will be filed with the Securities and Exchange Commission (the "SEC"), which will remove the company's securities from listing and registration on The Nasdaq Stock Market.

In addition, as reflected in its Annual Report on Form 10-K, which was filed with the SEC on February 27, 2009, Pharmos received an audit opinion from PricewaterhouseCoopers LLP, its independent registered public accounting firm, that expresses doubt about the ability of the company to continue as a going concern for a reasonable period of time.

As previously disclosed, the company is seeking to raise the additional capital necessary to complete the Dextofisopam Phase 2b trial. Assuming a financing is successful, the top line clinical data are expected to be available before the end of 2009.

About Pharmos Corporation

Pharmos discovers and develops novel therapeutics to treat a range of indications including specific diseases of the nervous system such as disorders of the brain-gut axis (IBS), pain/inflammation, and autoimmune disorders. The Company's lead product in development, dextofisopam, is undergoing Phase 2b testing in IBS patients. Dextofisopam has completed a Phase 2a IBS study in which it demonstrated a statistically significant effect compared to placebo on the primary efficacy endpoint of adequate relief (n=141, p=0.033). The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies targeting pain, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and other disorders. These are available for licensing / partnering. On February 18, 2009, Pharmos Corporation and its Israeli subsidiary, Pharmos Ltd., entered into an Asset Purchase Agreement with Reperio Pharmaceuticals Ltd. for the sale of the patent rights and technical know-how related to the compound known as PRS-639,058 and certain follow-on molecules.

Safe Harbor Statement

Statements made in this press release related to the business outlook and future financial performance of Pharmos, to the prospective market penetration of its drug products, to the development and commercialization of its pipeline products and to its expectations in connection with any future event, condition, performance or other matter, are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause results to differ materially from those set forth in these statements. Additional economic, competitive, governmental, technological, marketing and other factors identified in Pharmos' filings with the Securities and Exchange Commission could affect such results.

www.pharmoscorp.com


'/>"/>
SOURCE Pharmos Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pharmos Corporation Announces Modification to Dextofisopam Trial Size, Objectives Can Still Be Achieved
2. Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter
3. Pharmos Corporation Reports 2008 Third Quarter Results
4. Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results
5. Pharmos Restructures Operations in Israel
6. Santa Monica Media Corporation Files Extension Proxy With SEC to Complete Transaction
7. Dialysis Corporation of America Reports Fourth Quarter and Year Ended December 31, 2008 Results
8. Sysmex Corporation Announces Organizational Changes
9. Digirad Corporation Sells Arizona, Nevada Service Hubs
10. CVS Caremark Corporation Announces Quarterly Dividend
11. AMERIGROUP Corporation to Present at the Barclays Capital Global Healthcare Conference on March 10
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... , ... "I had a terrible time trying to get my grandson to ... the nebulizer had a more child-friendly design, then children would be more likely to ... NEBY to avoid the need to deliver medication via a nebulizer mask. The design ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in ... and patient safety. Only a few hospitals and facilities have earned this distinction. ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for Input to ... Medical Informatics . , Results of the comparative usability study demonstrate that a ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s leading digital ... aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media ... Jr said, “CURE Media Group is honored to team up with Upstage Lung Cancer ...
(Date:12/8/2016)... ... ... Premier Fitness Camp (PFC) and The Chopra Center for Wellbeing announced today the ... their world headquarters of Omni La Costa Resort & Spa in San Diego. , ... loss, personal development, a healthy lifestyle, or mental and physical healing. The week-long wellness ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec 8, 2016 Research and Markets has announced ... report to their offering. ... This report analyzes the worldwide markets for Endodontic Supplies ... Canada , Japan , Europe ... Rest of World. Annual estimates and forecasts are provided for the ...
(Date:12/8/2016)... Dec. 8, 2016   TriNetX , the ... Children,s Hospital signed a membership agreement to ... development of new cures. The TriNetX ... 57 million patients globally, biopharmaceutical companies and contract ... improve protocol design, site selection, patient recruitment, and ...
(Date:12/8/2016)... 8, 2016  Valeant Pharmaceuticals International, Inc. (NYSE: ... today announced positive results from a Phase 3, ... the safety and efficacy of IDP-118 (halobetasol propionate ... psoriasis. Within the Phase 3 ... severe psoriasis, IDP-118 showed statistical significance to vehicle ...
Breaking Medicine Technology: